SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
CRSP reported Third quarter ended September 30, 2026 results. The stock moved 0.0% on the print.
CRSPearnings

Earnings reactions, page 7

CRISPR Therapeutics (CRSP) Q3 FY2026 earnings

November 3, 2026 · SharpeIQ Research Desk

Reported results

  • CASGEVY generated $99 million in revenue for the third quarter of 2026.
  • Research and development expenses were $71.9 million for the third quarter of 2026.
  • Acquired in-process research and development expenses were $11.7 million for the third quarter of 2026.
  • General and administrative expenses were $17.9 million for the third quarter of 2026.
  • Collaboration expense, net, was $41.3 million for the third quarter of 2026.
  • Net loss was $111.4 million for the third quarter of 2026.

Price and volatility reaction

The stock moved 0.0% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -4.4 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release49.992026-11-02
Close after release49.992026-11-03
Realised move0.0%close to close
30d ATM IV change-4.4 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-02 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →